A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly

By Dawson L.K.   Jodrell D.I.   Bowman A.   Rye R.   Byrne B.   Bernareggi A.   Camboni G.   Smyth J.F.  

European Journal of Cancer, Vol. 36, Iss. 18, 2000-12 ,pp. : 2353-2359

Elsevier

Access to resources Recommend Favorite

Phase I study of a weekly schedule of a fixed dose of cisplatin and escalating doses of paclitaxel in patients with advanced oesophageal cancer

By Polee M.B.   Verweij J.   Siersema P.D.   Tilanus H.W.   Splinter T.A.W.   Stoter G.   Van der Gaast A.  

European Journal of Cancer, Vol. 38, Iss. 11, 2002-07 ,pp. : 1495-1500

Elsevier

Access to resources Recommend Favorite

A phase I trial of amsalog (CI-921) administered by intravenous infusion using a 5-day schedule

By Fyfe D.   Price C.   Langley R.E.   Pagonis C.   Houghton J.   Osborne L.   Woll P.J.   Gardner C.   Baguley B.C.   Carmichael J.  

Cancer Chemotherapy and Pharmacology, Vol. 47, Iss. 4, 2001-04 ,pp. : 333-337

Springer Publishing Company

Access to resources Recommend Favorite

A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound, administered as a 24-h continuous infusion in patients with advanced solid tumors

By Gordon Michael   Ilaria Robert   Alwis Dinesh   Mendelson David   McKane Scott   Wagner Margaret   Look Katherine   LoRusso Patricia  

Cancer Chemotherapy and Pharmacology, Vol. 71, Iss. 1, 2013-01 ,pp. : 21-27

Springer Publishing Company

Access to resources Recommend Favorite

Phase I and pharmacokinetic studies of PNU-159548, a novel alkycycline, administered intravenously to patients with advanced solid tumours

By de Jonge M.J.A.   Verweij J.   van der Gaast A.   Valota O.   Mora O.   Planting A.S.T.   Mantel M.A.   Bosch S.V.D.   Lechuga M.J.   Fiorentini F.   Hess D.   Sessa C.  

European Journal of Cancer, Vol. 38, Iss. 18, 2002-12 ,pp. : 2407-2415

Elsevier

Access to resources Recommend Favorite